News
The most up to date reporting and breakthroughs in anal cancer and HPV research, and Anal Cancer Foundation’s latest activities and events.
IANS Anal Cancer Prevention Screening Toolkit
Why We Need Anal Cancer Screening Anal cancer is preventable, yet thousands of people are diagnosed with it each year. That can change with awareness, open conversations, and access to screening. Before cancer develops, early cell changes can form in the anal canal. These are called high-grade squamous intraepithelial lesions (HSIL). These pre-cancerous changes usually… read more
Let’s Talk Anal Cancer: Elevating Community Voices
Advancing progress in anal cancer involves more than scientific innovation – it requires engaging people affected by anal cancer in open dialogue and listening closely. We sat down with Incyte, a biotechnology company invested in the treatment of anal cancer, to learn more about their research efforts, commitment to patients and how community voices influenced… read more
NavDx Test gains expanded Medicare coverage: What anal cancer patients should know
In November, Medicare coverage was established for the NavDx® test to be used in the surveillance of patients with previously treated anal squamous cell carcinoma (ASCC). In this article we share information for patients and caregivers What is the NavDx test? The NavDx® test, developed and performed exclusively by Naveris®, is the first and most… read more
DPD Deficiency Testing before 5-FU Treatment for Anal Cancer: What you should know
What patients and caregivers need to know about the latest NCCN guidance and DPD testing before treatment for anal cancer. What is NCCN? The National Comprehensive Cancer Network is a non-profit dedicated to cancer care. The NCCN creates national guidelines that are followed in the United States. What’s DPD and why does it matter? –… read more
FDA APPROVE RETIFANLIMAB-DWLR (ZYNYZ®) FOR ADVANCED ANAL CANCER: WHAT YOU SHOULD KNOW
On May 15, 2025, the U.S. Food and Drug Administration (FDA) approved a new treatment called retifanlimab-dwlr (Zynyz®) for people with advanced anal cancer. This approval brings new option to patients facing this challenging disease. Please note: The information in this post pertains to treatment approved by the U.S. FDA and is intended for U.S…. read more
10 year of Peer to Peer Support. Help us support 10 more.
Dear friends, At the Anal Cancer Foundation we believe that no one should face an anal cancer diagnosis alone. In 2024, our Peer to Peer Support Programme celebrated a decade of making this a reality! Influenced by our own experience, and as the only organization dedicated to anal cancer patients and their families, the Peer… read more
The Role of Circulating Tumor DNA in Management of Patients with Anal Cancer
Our latest free, expert-led webinar with Dr. Van Morris from the MD Anderson Cancer Center took place on December 3, 2024. In the session Dr. Morris will dive into the role of circulating tumor DNA (ctDNA)—a blood-based test—changing how we manage and monitor cancers like colorectal and anal. This technology could help us detect which… read more
Fertility Preservation Options During Anal Cancer Treatment
Join reproductive endocrinologist Dr. Alexander M. Kotlyar and urologist Dr. Jacob Khurgin for an important discussion about the impacts of anal cancer treatment on fertility for both men and women. Whether you’re interested in fertility preservation or simply want to learn more about your options as a thriver, this webinar is packed with invaluable insights.
ctDNA Detection as a Biomarker of Outcomes in Anal Cancer Care
The annual meeting of The American Society of Clinical Oncology (ASCO) always produces headlines about advances made in detection, treatment and prevention of cancer, and this year those headlines include news for the anal cancer community. Dr Van Morris and his team at MD Anderson announced results from their study of circulating tumor DNA (ctDNA)…. read more
Webinar: Voices of Resilience: Personal Journeys and Self-Advocacy in Anal Cancer
On March 21st, Anal Cancer Awareness Day, a panel of thrivers at all stages of their cancer journeys shared powerful stories of resiliency and self-advocacy. We are incredibly grateful to them and to the participants who watched, asked questions, and engaged in community-building! In case you could not join us, or want to just rewatch and… read more
